Carbon Nano Technology Taiwan Sells 46,000 Shares of Ainos (NASDAQ:AIMD) Stock

Ainos, Inc. (NASDAQ:AIMD) major shareholder Carbon Nano Technology Taiwan sold 46,000 shares of the firm’s stock in a transaction dated Wednesday, January 28th. The stock was sold at an average price of $2.17, for a total value of $99,820.00. Following the sale, the insider directly owned 989,925 shares in the company, valued at approximately $2,148,137.25. This trade represents a 4.44% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Large shareholders that own at least 10% of a company’s stock are required to disclose their transactions with the SEC.

Carbon Nano Technology Taiwan also recently made the following trade(s):

• On Friday, January 9th, Carbon Nano Technology Taiwan sold 431 shares of Ainos stock. The shares were sold at an average price of $1.86, for a total value of $801.66.
• On Thursday, January 8th, Carbon Nano Technology Taiwan sold 850 shares of Ainos stock. The stock was sold at an average price of $1.80, for a total transaction of $1,530.00.

Ainos Price Performance

NASDAQ:AIMD opened at $2.00 on Friday. The company has a debt-to-equity ratio of 1.10, a current ratio of 2.96 and a quick ratio of 2.67. The company has a 50 day moving average price of $1.99 and a 200-day moving average price of $2.84. Ainos, Inc. has a 1-year low of $1.61 and a 1-year high of $4.50. The firm has a market cap of $9.62 million, a price-to-earnings ratio of -0.50 and a beta of 2.45.

Ainos (NASDAQ:AIMD) last announced its quarterly earnings results on Thursday, November 13th. The company reported ($0.64) earnings per share (EPS) for the quarter. The company had revenue of $0.00 million for the quarter.

Institutional Investors Weigh In On Ainos

A hedge fund recently bought a new stake in Ainos stock. Two Sigma Investments LP acquired a new position in shares of Ainos, Inc. (NASDAQ:AIMD) in the 3rd quarter, according to its most recent filing with the SEC. The fund acquired 23,008 shares of the company’s stock, valued at approximately $80,000. Two Sigma Investments LP owned approximately 0.48% of Ainos at the end of the most recent quarter.

Analysts Set New Price Targets

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of Ainos in a research note on Monday, December 29th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company has an average rating of “Sell”.

About Ainos

Ainos, Inc (NASDAQ: AIMD) is a clinical‐stage biopharmaceutical company dedicated to developing inhalation therapies for patients with chronic pulmonary disorders. The company’s proprietary platform centers on a dry powder inhalation technology designed to deliver therapeutic agents directly to the lungs, potentially improving drug distribution and reducing systemic side effects compared to traditional oral or intravenous formulations.

The lead product candidate, AI‐401, is an inhaled formulation of ibuprofen in a dry powder format.